RecruitingPsoriasis Vulgaris
Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Biologics, such as brodalumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis. But they are costly for health care systems and prescribed according to a 'one dose fits all' dosing regimen, leading to potential over- and undertreatment. Within this study we aim to investigate the predictive value of early serum trough levels of brodalumab and determine the therapeutic window of brodalumab in psoriasis patients.
Sponsor: University Hospital, Ghent
You may qualify if…
- ✓ 1. Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis
- ✓ 2. Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
You may not qualify if…
- ✕ 1. Participants who have currently a predominant nonplaque form of psoriasis
- ✕ 2. Participants who are pregnant, nursing or planning a pregnancy
- ✕ 3. Participants who are unable or unwilling to undergo multiple venapunctures
- ✕ 4. Participants who are treated according to a different dosing schedule than standard dosing of brodalumab
Source: ClinicalTrials.gov · NCT04080635 · last updated 2024-09-19